Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study

INTRODUCTION: A growing number of biologics have recently been approved in China for psoriasis treatment, and some of these are eligible for Chinese medical insurance, resulting in a significant increase in the number of patients receiving these biologics. Nevertheless, real-world data on the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Gaojie, Gu, Yuanxia, Zou, Qin, Wang, Yiyi, Xiao, Yue, Xia, Dengmei, Zhan, Tongying, Zhou, Xingli, Wang, Qian, Yan, Wei, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464289/
https://www.ncbi.nlm.nih.gov/pubmed/35953612
http://dx.doi.org/10.1007/s13555-022-00787-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464289/
https://www.ncbi.nlm.nih.gov/pubmed/35953612
http://dx.doi.org/10.1007/s13555-022-00787-x

Ejemplares similares